Metavia Inc. has presented new clinical data on its pipeline targeting cardiometabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company highlighted its lead candidate DA-1726, a novel GLP1R/GCGR dual agonist, which demonstrated weight loss of up to 6.3% and reductions in fasted glucose and waist circumference over a 26-33 day period in a Phase 1 study. The candidate was generally well-tolerated, with mild gastrointestinal events reported and no treatment-related discontinuations. Metavia also reported positive Phase 2a top-line data for Vanoglipel (DA-1241) in MASH, confirming primary endpoint achievement and a favorable safety profile. Additional dose-finding and longer-duration studies are ongoing. You can access the full presentation through the link below.